FSD Pharma Files 6-K, Submits Phase-1b Clinical Trial Application
Ticker: QNTM · Form: 6-K · Filed: Mar 11, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, filing, pharma
TL;DR
FSD Pharma filed a 6-K, submitted Phase-1b trial app. Bullish for pipeline progress.
AI Summary
FSD Pharma Inc. filed a Form 6-K on March 11, 2024, to report its activities for March 2024. The filing includes a press release (Exhibit 99.1) announcing that FSD Pharma has submitted a Phase-1b clinical trial application. The company's principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Why It Matters
This filing indicates FSD Pharma is advancing its drug development pipeline, potentially leading to new therapeutic options if the clinical trial is successful.
Risk Assessment
Risk Level: medium — Clinical trial submissions carry inherent risks related to trial success, regulatory approval, and market adoption.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- March 11, 2024 (date) — Filing Date
- March 2024 (date) — Reporting Period
- Phase-1b (clinical_trial_phase) — Clinical Trial Stage
FAQ
What is the specific drug or indication for the Phase-1b clinical trial?
The provided filing does not specify the drug or indication for the Phase-1b clinical trial; it only states that the application has been submitted.
When is the Phase-1b clinical trial expected to commence?
The filing does not provide an expected start date for the Phase-1b clinical trial.
What is the outcome of the Phase-1b clinical trial application submission?
The filing states that the application has been submitted, but does not indicate whether it has been approved or is pending review.
Who is the primary contact for FSD Pharma Inc. regarding this filing?
Nathan Coyle, Chief Financial Officer, signed the report on behalf of FSD Pharma Inc.
What is the standard industrial classification for FSD Pharma Inc.?
The Standard Industrial Classification for FSD Pharma Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-03-11 08:00:17
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 16KB
- fsd_ex991img5.jpg (GRAPHIC) — 6KB
- 0001654954-24-002908.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: March 11, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3